Shares of SciSparc Ltd. (SPRC) are up 48% on Wednesday after the company shared the topline results of its Phase IIa clinical trial, which indicated that SCI-110 is a safe and effective treatment option for this debilitating symptom of Alzheimer's Disease (AD).